typhoid vaccine
Vaccinemarketed
Approved
Jul 1, 1896
The Vi capsular polysaccharide vaccine is a typhoid vaccine recommended by the World Health Organization for the prevention of typhoid. The vaccine was first licensed in the US in 1994 and is made from the purified Vi capsular polysaccharide from the Ty2 Salmonella Typhi strain; it is a subunit vaccine. — Wikipedia
Clinical trial activity
12 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
6
Phase 3
2
Phase 4
2
Earliest trial started Mar 1, 2012 (NCT01582321)
Timeline
Indications
Approved for
Mechanism of action
- Salmonella typhiImmunity, active
Salmonella typhi immunity, active
Approval history
- approvedJul 1, 1896
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVi capsular polysaccharide vaccine ↗
- ChEMBLCHEMBL2108822 ↗
- WikipediaTyphoid vaccine ↗
Also known as
- typherix
- typhoid vaccine
- typhoid vaccine
- typhoid vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04830371 | Phase 2/Phase 3 (Phase 3) | Sep 7, 2020 | EuBiologics Co.,Ltd |
| NCT03889158 | Phase 4 | Apr 30, 2019 | University of Illinois at Chicago |
| NCT03614533 | Phase 2 | Oct 15, 2018 | Bill and Melinda Gates Foundation, Groupe de Recherche Action en Santé (GRAS), Burkina Faso, University of Maryland |
| NCT03299426 | Phase 3 | Feb 21, 2018 | Bill and Melinda Gates Foundation, University of London, University of Malawi, University of Maryland, Wellcome Trust |
| NCT02628054 | N/A | Feb 1, 2015 | University of Oxford |
| NCT02338778 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Jinan University |
| NCT02338804 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Jinan University |
| NCT02338752 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Jinan University |
| NCT02338700 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Jinan University |
| NCT02415387 | N/A | Jan 1, 2014 | Ohio State University |
| NCT02121145 | Phase 4 | Oct 1, 2013 | University of Helsinki |
| NCT01582321 | Early Phase 1 (Phase 1) | Mar 1, 2012 | University of London |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jinan University | Academic/Hospital | 4 | 4 | 1 | 2015 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 2 | 0 | 2 | 2018 |
| University of London | Academic/Hospital | 2 | 1 | 2 | 2012 |
| University of Maryland | Academic/Hospital | 2 | 2 | 2 | 2018 |
| EuBiologics Co.,Ltd | For profit | 1 | 1 | 1 | 2020 |
| Groupe de Recherche Action en Santé (GRAS), Burkina Faso | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Helsinki | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Illinois at Chicago | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Malawi | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Wellcome Trust | Academic/Hospital | 1 | 0 | 1 | 2018 |
12 organizations
Page 1 / 1